Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.
FORGETDIABETES aims to develop a long-term automated insulin delivery system. This system should enable optimal glucose control without patient intervention. The initiative, funded by the European Union’s Horizon 2020 research and innovation program, offers support from basic research to product development.
Glucotrack said in a news release that FORGETDIABETES wants to produce a bionic, invisible pancreas. Such technology could free people with type 1 diabetes from therapeutic actions and psychological burden. The company’s part in this is to contribute its investigational continuous blood glucose monitor (CBGM). This provides real-time glucose readings to drive insulin delivery decisions for the bionic pancreas.
Rutherford, New Jersey-based Glucotrack develops a long-term implantable CBGM. The device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution.
Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
Claudio Cobelli, emeritus professor of bioengineering at the University of Padova in Padova, Italy, serves as the initiative’s coordinator. Cobelli says Glucotrack’s CBGM delivers longevity, accuracy and convenience, making it “an ideal complement” for a bionic pancreas.
“We are thrilled to be part of the groundbreaking FORGETDIABETES initiative, which aligns perfectly with our mission to transform diabetes management through innovative and accessible technology,” said Paul Goode, President and CEO of Glucotrack. “Integration into automated insulin delivery systems is a key priority for us. We are honored to join FORGETDIABETES to develop a fully implantable closed loop system for people living with diabetes.”
